EORTC Bladder Cancer Recurrence & Progression Score Calculator

About the EORTC Bladder Cancer Recurrence & Progression Score Calculator

The EORTC Bladder Cancer Recurrence and Progression Score Calculator implements the European Organisation for Research and Treatment of Cancer (EORTC) risk tables for non-muscle-invasive bladder cancer (NMIBC). Developed by Sylvester et al. (2006) from analysis of 2,596 patients in seven EORTC trials, these scoring systems predict the probability of tumor recurrence and muscle-invasive progression based on six clinical and pathological factors.

Non-muscle-invasive bladder cancer (stages Ta, T1, and CIS) accounts for approximately 75% of newly diagnosed bladder cancers. While generally less lethal than muscle-invasive disease, NMIBC has high recurrence rates (50–70% within 5 years) and 10–30% of cases progress to muscle-invasive disease, where prognosis is significantly worse. The EORTC risk tables help stratify patients into risk groups to guide surveillance intensity, intravesical therapy decisions, and timing of radical cystectomy.

The six scoring factors are: number of tumors, tumor size, prior recurrence rate, T category (Ta vs. T1), presence of concurrent carcinoma in situ (CIS), and histologic grade. Separate scores are calculated for recurrence risk (0–17 points) and progression risk (0–23 points), each mapping to defined risk groups with specific 1-year and 5-year probability estimates.

When This Page Helps

NMIBC management ranges from surveillance alone (low risk) to early radical cystectomy (very high risk). The EORTC risk tables objectively classify patients to guide these decisions. Without risk stratification, low-risk patients may be overtreated and high-risk patients undertreated. It shows both recurrence and progression scores with corresponding probability estimates.

How to Use the Inputs

1. Select the number of tumors found at transurethral resection (TUR).
2. Select the largest tumor diameter (<3 cm or ≥3 cm).
3. Indicate prior recurrence rate (primary vs. recurrent and frequency).
4. Select the T category (Ta = confined to mucosa; T1 = invades lamina propria).
5. Indicate whether concurrent carcinoma in situ (CIS) is present.
6. Select the tumor grade (G1/low, G2/intermediate, or G3/high grade).

Example Calculation

Tips & Best Practices

• CIS and T1 stage are the strongest predictors of progression — patients with both features should be discussed for early cystectomy.
• The EORTC tables were developed before widespread use of BCG maintenance, so actual progression rates with optimal BCG may be lower.
• Consider the Spanish CUETO tables as an alternative that accounts for BCG treatment effects.
• High-grade T1 with CIS on re-staging TUR is particularly high-risk — EAU guidelines recommend considering immediate cystectomy.
• A second (re-staging) TUR at 2–6 weeks is recommended for all T1 tumors and when initial resection was incomplete.
• Enhanced cystoscopy (blue light, NBI) improves detection of CIS and reduces residual tumor rates.

EORTC Score Derivation

Sylvester et al. analyzed individual patient data from seven EORTC randomized trials (1979–1999) including 2,596 patients with Ta/T1 NMIBC who received some form of intravesical therapy (not BCG maintenance). Using multivariate analysis, they identified six independent predictors of recurrence and progression, weighted each factor, and created scoring systems mapping to probability tables. The original publication (European Urology, 2006) remains one of the most cited papers in bladder cancer management.

Role of Molecular Markers

Beyond clinical and pathological factors, molecular markers are increasingly used to refine risk stratification. p53 overexpression, Ki-67 proliferation index, CK20 expression pattern, and FGFR3 mutation status provide additional prognostic information. Genomic classifiers (e.g., Decipher Bladder) are in development. Currently, these markers complement but don't replace the EORTC risk tables in clinical practice.

Treatment by Risk Group

Low risk: single immediate post-TUR chemotherapy instillation (mitomycin C or epirubicin), then surveillance. Intermediate risk: intravesical chemotherapy (mitomycin C × 6–8 weekly, or BCG induction). High risk: BCG induction (6 weekly instillations) followed by BCG maintenance (1–3 years per SWOG protocol). Very high risk / BCG failure: consider radical cystectomy, clinical trials, or alternative intravesical agents (gemcitabine, pembrolizumab, TAR-200).

Frequently Asked Questions

• What is non-muscle-invasive bladder cancer?

  NMIBC includes tumors confined to the bladder mucosa (Ta — papillary, limited to urothelium), lamina propria (T1 — invades subepithelial connective tissue), and CIS (flat, high-grade confined to urothelium). They haven't invaded the detrusor muscle (T2+). NMIBC accounts for ~75% of bladder cancers and is treated with TUR ± intravesical therapy, while muscle-invasive disease typically requires cystectomy or chemoradiation.

• What is the difference between recurrence and progression?

  Recurrence means the tumor comes back at the same or similar stage — the cancer returns but hasn't become more invasive. Progression means the cancer advances to a higher stage (typically Ta→T1 or T1→T2+, or to lymph node/distant metastasis). Progression is the more clinically significant outcome because it may require radical cystectomy and has worse long-term survival.

• What is BCG therapy?

  BCG (Bacillus Calmette-Guérin) is a live attenuated tuberculosis vaccine instilled into the bladder to stimulate the immune system against cancer cells. It's the most effective intravesical therapy for intermediate and high-risk NMIBC, reducing both recurrence and progression. Maintenance BCG (typically weekly × 3, repeated at 3, 6, 12, 18, 24, 30, 36 months) is recommended for high-risk patients.

• When should cystectomy be considered?

  Early radical cystectomy should be discussed for: BCG-unresponsive disease (recurrence/progression during or after BCG), very high-risk features (T1G3 + CIS, especially on re-staging TUR), lymphovascular invasion, variant histology (micropapillary, plasmacytoid), and deeply invasive T1 tumors. Delaying cystectomy when the tumor is still NMIBC offers better outcomes than waiting for muscle invasion.

• How reliable are the EORTC risk tables?

  The EORTC tables were derived from a large cohort (2,596 patients) and have been externally validated. However, they were developed before routine re-staging TUR, BCG maintenance, and enhanced cystoscopy. They may overestimate risk in patients receiving optimal modern treatment. The Spanish CUETO model, which accounts for BCG use, may be more appropriate for BCG-treated patients.

• What surveillance schedule is recommended?

  Based on risk: Low risk (TaG1 single, <3cm): cystoscopy at 3 months, then 9 months, then annually for 5 years. Intermediate risk: cystoscopy every 3 months for 2 years, every 6 months for 3 years, then annually. High risk: cystoscopy every 3 months for 2 years, every 6 months for 3 years, then annually for life. CT urography annually for high-risk patients.